Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on pioneering transformative cell and exosome-based therapies to treat and prevent a diverse range of diseases and disorders. Their lead therapeutic, CAP-1002, is an allogeneic cell therapy derived from heart tissue. This candidate has successfully completed its Phase III clinical trial for patients afflicted with late-stage Duchenne muscular dystrophy (DMD). CAP-1002 is simultaneously progressing through Phase II clinical testing to address cytokine storm associated with SARS-CoV-2. Beyond CAP-1002, the company is advancing CAP-2003 through preclinical development, aiming to treat trauma-related injuries and medical conditions. Furthermore, Capricor is developing two vaccine candidates with the potential to prevent COVID-19. Capricor collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, supporting its use in DMD and other indications. The company was established in 2005 and is headquartered in San Diego, California.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Target Price
The average target price of CAPR is 55 and suggests 119% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas